Trastuzumab deruxtecan (T-Dxd DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH

Vaz Batista, M.Perez-Garcia, J. M.Llombart Cussac, A.Cortez, P.Ruiz Borrego, M.De la Haba, J.Cejalvo, J. M.Racca, F.Servitja, S.Blanch, S.Lema, L.Galan Garmaje, M.Fernandez-Abad, M.Fernandez, A.Iranzo, V.Gonzalez-Santiago, S.Gion, M.Nave, M.Cortes, J.Braga, S.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/25937enTrastuzumab deruxtecan (T-Dxd DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAHconference outputopen access10.1016/j.annonc.2021.08.6131569-8041https://doi.org/10.1016/j.annonc.2021.08.613700527700309